FibroGen, AstraZeneca Up After Roxadustat Data

Date : 11/08/2019 @ 8:19PM
Source : Dow Jones News
Stock : Astrazeneca Plc (AZN)
Quote : 7878.0  171.0 (2.22%) @ 4:35PM
Astrazeneca share price Chart

FibroGen, AstraZeneca Up After Roxadustat Data

AstraZeneca (NYSE:AZN)
Historical Stock Chart

3 Months : From Oct 2019 to Jan 2020

Click Here for more AstraZeneca Charts.

By Michael Dabaie


AstraZeneca PLC (AZN) and FibroGen Inc. (FGEN) said roxadustat Phase III program pooled analyses showed positive efficacy and no increased cardiovascular risk in patients with anemia from chronic kidney disease.

FibroGen shares turned positive after trading down earlier in the session, recently up 9.5%, to $41.56. AstraZeneca ADRs also turned positive, recently up 0.6%, at $47.09.

In non dialysis-dependent patients receiving roxadustat, the risk of major adverse CV events, defined as all-cause mortality, stroke and myocardial infarction, MACE+, which is defined as MACE, unstable angina requiring hospitalization and congestive heart failure requiring hospitalization, and all-cause mortality was comparable to placebo, the companies said.

In incident dialysis patients, roxadustat had a lower risk of MACE and MACE+ and showed a trend towards lower risk of all-cause mortality relative to epoetin alfa.


Write to Michael Dabaie at


(END) Dow Jones Newswires

November 08, 2019 15:04 ET (20:04 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20200117 19:38:07